News | Intra-Vascular Ultrasound (IVUS) | February 29, 2016

Study Finds Intravascular Ultrasound Beneficial in Diagnosing Vein Obstructions

IVUS finds 88 percent more lesions than gold-standard multiplanar X-ray venography

Philips, Volcano, IVUS, vein obstruction diagnosis, multiplanar X-ray venography, VIDIO study

February 29, 2016 — Philips announced that new clinical trial data demonstrates the benefits of its intravascular ultrasound (IVUS) technology in the diagnosis of iliofemoral venous obstruction i.e. narrowed or blocked leg veins. The study, which compared IVUS to conventional contrast-enhanced X-ray imaging of the veins (also known as multiplanar X-ray venography), was presented by Paul J. Gagne, M.D., chief of vascular surgery at Norwalk Hospital in Norwalk, Conn.

In image-guided treatments of the blood vessels, there is an increasing trend to use IVUS catheters that are capable of producing ultrasound images of the interior of blood vessels. There is a growing body of clinical evidence that the use of this technology in conjunction with interventional X-ray helps improve procedural outcomes.

In the 100-patient prospective multicenter Venogram Versus Intravascular Ultrasound for Diagnosing Iliofemoral Vein Obstruction (VIDIO) study, 29 percent of patients were assessed to be free of lesions based on their X-ray venogram results, but had lesions detected by Philips Volcano’s phased-array IVUS technology. The results of the study, in which IVUS in total detected 88 percent more lesions than multiplanar X-ray venography (as assessed by investigators at the point-of-care), were announced at the American Venous Forum 28th annual meeting.

Iliac/common femoral vein obstruction (ICFVO) is a significant cause of chronic venous insufficiency (CVI) — a condition that is estimated to affect between 10-35 percent of adults in the United States, resulting in approximately 4.6 million lost workdays. Iliofemoral vein obstruction, which can eventually lead to swelling, chronic pain and ulceration, can be treated via angioplasty and stenting with profound benefits to the patient’s quality of life. However, many patients exhibiting symptoms may not be diagnosed with venography. There is, therefore, a real need for better ways to diagnose the condition.

“These results of the VIDIO study clearly show that IVUS is better at detecting lesions than multiplanar X-ray venography, the prior imaging gold standard,” said Gagne, global principal investigator of the study. “IVUS is now my preferred imaging modality of choice for identifying this treatable condition, and the VIDIO study shows how well these patients can do with the appropriate treatment.”

The study was designed to prospectively compare the diagnostic performance of conventional multiplanar venography versus IVUS for diagnosing and treating ICFVO; and to characterize patient response to iliofemoral vein intervention in terms of clinical improvement and quality of life over six months of follow-up.

Between July 2014 and July 2015, the study enrolled 100 patients with advanced venous insufficiency (CEAP* score 4, 5 and 6) at 11 U.S. and three European centers. Each patient had a multiplanar venogram performed, with an initial lesion characterization and treatment strategy recorded by the interventionalist based on the venogram. An assessment with Philips Volcano phased-array IVUS was then performed, with a second lesion characterization and treatment strategy recorded by the interventionalist. Stenting treatment was subsequently performed at the discretion of the interventionalist. All patients were followed for six months after the index procedure.

Across the full 100 patients enrolled, according to investigator readings at the time of the index procedure, IVUS detected 88 percent more lesions than multiplanar venography (124 vs 66) (P < .0001). In addition, 29 percent of patients were ruled negative by venograms, while showing positive findings from IVUS (19 vs 48).

For more information: www.volcanocorp.com

Related Content

News | Cath Lab | February 23, 2018
February 23, 2018 — CorFlow Therapeutics AG announced that the company will present new insights into the coronary mi
Teleflex Launches Next-Generation Sympro Elite and Expro Elite Snares
Technology | Cath Lab | February 07, 2018
Teleflex Inc. has announced 510(k) clearance by the U.S. Food and Drug Administration (FDA) and U.S. commercial launch...
SCAI Advocacy Committee Highlights Reimbursement Reform Efforts in 2017
News | Cath Lab | January 30, 2018
The Society for Cardiovascular Angiography and Interventions (SCAI) highlighted the efforts of its Advocacy Committee...
IAC Releases Cardiovascular Catheterization Accreditation Program
News | Cath Lab | January 25, 2018
January 25, 2018 – The Intersocietal Accreditation Commission (IAC) announced the release of its Cardiovascular Cathe
Videos | Cath Lab | January 04, 2018
Bernadette Speiser, BSN, MSN, CCRN, RCIS, a cardiac cath/EP nurse at Palo Alto Veterans Hospital, Palo Alto, Calif.,
FDA Initiates Class I Recall of Sterilmed Reprocessed Agilis Steerable Introducer Sheath
News | Cath Lab | January 04, 2018
The U.S. Food and Drug Administration (FDA) announced a Class I recall of Sterilmed’s Agilis Steerable Introducer...
The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA atherectomy system. Athar Ansari, M.D.

The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA system. 

Feature | Cath Lab | November 24, 2017 | Athar Ansari, M.D., FACC
As debates about the current state and future of healthcare rage in Congress, the media and healthcare settings acros
Videos | Cath Lab | November 08, 2017
Juan Granada, M.D., Cardiovascular Research Foundation president and chief executive officer, shares his insights on
Results of the ORBITA study found no difference in exercise time after six weeks in patients with stable angina who received percutaneous coronary intervention (PCI) versus a placebo treatment. TCT 2017
Feature | Cath Lab | November 06, 2017
November 6, 2017 – Results from ORBITA, a prospective multi-center randomized blinded placebo-controlled study, found
Overlay Init